Patent

Mustang Bio Announces MB-101 (IL13Rα2‐targeted CAR T cells) Scientific Presentations at Upcoming Virtual Conferences

Retrieved on: 
Tuesday, September 28, 2021
Patent, Glioblastoma, Securities Act of 1933, Regulation, City of Hope, CD19, Private Securities Litigation Reform Act, NASDAQ, Translation, Conference, U.S. Securities and Exchange Commission, Hematological Cancer Research Investment and Education Act, Association, Immunoglobulin G, Lists of diseases, Ownership, Medulloblastoma, American Society of Clinical Oncology, CD137, Fortress Biotech, Phenotype, Mustang, CAR, Ependymoma, Research, Heritage, Forward-looking statement, Brain, Securities Exchange Act of 1934, City, SEC, Society, GLOBE, Pharmaceutical industry, Vaccine

Additional information about the brain cancer clinical trials can be found on clinicaltrials.gov using identifiers NCT04661384 , NCT02208362 and NCT04003649 .

Key Points: 
  • Additional information about the brain cancer clinical trials can be found on clinicaltrials.gov using identifiers NCT04661384 , NCT02208362 and NCT04003649 .
  • Mustang is developing MB101 as an optimized CAR T product incorporating enhancements in CAR design and T cell engineering to improve antitumor potency and T cell persistence.
  • Mustang has partnered with top medical institutions to advance the development of CAR T therapies across multiple cancers, as well as a lentiviral gene therapy for X-linked severe combined immunodeficiency.
  • Mustang is registered under the Securities Exchange Act of 1934, as amended, and files periodic reports with the U.S. Securities and Exchange Commission (SEC).

Longeveron Announces Multiple Presentations at the 11th Annual International Conference on Frailty & Sarcopenia Research

Retrieved on: 
Tuesday, September 28, 2021
Microsoft, Patent, Goal, Safety, Bone marrow, Investor, Ageing, NASDAQ, Intention, Conference, HLHS, Patient, Disability, Adult, Intussusception (medical disorder), Hypoplastic left heart syndrome, Company, Terminology, Efficacy, HERA, Placebo-controlled study, Metabolic syndrome, Cell, Randomness, Forward-looking statement, SEC, GLOBE, Disorder, Pharmaceutical industry, Vaccine

A live panel with Dr. Ruiz and Longeveron management will follow the presentation.

Key Points: 
  • A live panel with Dr. Ruiz and Longeveron management will follow the presentation.
  • Those interested in registering for the conference can find more information at the conference website: https://frailty-sarcopenia.com/ .
  • All three presentations will be posted to Longeverons website after the conference under Events & Presentations in the Investors section of the Companys website at investors.longeveron.com .
  • Longeveron is a clinical stage biotechnology company developing cellular therapies for specific aging-related and life-threatening conditions.

Fortress Biotech to Participate in the Benzinga Healthcare Small Cap Conference

Retrieved on: 
Tuesday, September 28, 2021
Technology, Patent, Therapy, Securities Act of 1933, Regulation, Drug Quality and Security Act, Event, City of Hope, Hospital, Private Securities Litigation Reform Act, NASDAQ, News, Conference, New media, Fortification, Degenerative disease, Fred Hutchinson Cancer Research Center, Telecommunication, Fortress Biotech, AstraZeneca, COVID-19, Research, Drug development, Human body, Forward-looking statement, Nationwide, Securities Exchange Act of 1934, City, SEC, GLOBE, Fine chemical, Medical device

NEW YORK, Sept. 28, 2021 (GLOBE NEWSWIRE) -- Fortress Biotech, Inc. (NASDAQ: FBIO) (Fortress), an innovative biopharmaceutical company focused on acquiring, developing and commercializing or monetizing promising biopharmaceutical products and product candidates cost-effectively, today announced that Lindsay A. Rosenwald, M.D., Chairman, President and Chief Executive Officer, will participate in the Benzinga Healthcare Small Cap Conference, scheduled to take place from September 29-30, 2021.

Key Points: 
  • NEW YORK, Sept. 28, 2021 (GLOBE NEWSWIRE) -- Fortress Biotech, Inc. (NASDAQ: FBIO) (Fortress), an innovative biopharmaceutical company focused on acquiring, developing and commercializing or monetizing promising biopharmaceutical products and product candidates cost-effectively, today announced that Lindsay A. Rosenwald, M.D., Chairman, President and Chief Executive Officer, will participate in the Benzinga Healthcare Small Cap Conference, scheduled to take place from September 29-30, 2021.
  • Details of the events are as follows:
    Presentation: The company will present a corporate update on Thursday, September 30, 2021, at 11:30 a.m.
  • ET and will participate in one-on-one meetings during the conference.
  • Panel: Dr. Rosenwald will also participate in a panel discussion entitled, Immuno-Oncology: Harnessing the Human Body's Power to Battle Cancer, on Thursday, September 30, 2021, at 12:35 p.m.

Cue Biopharma Announces Publication in Nature Journal, Scientific Reports, of Immunotherapeutic Platforms Immuno-STAT and Neo-STAT

Retrieved on: 
Tuesday, September 28, 2021
Food, Infection, Patent, Result, Cancer, Scientific Reports, Policy, Cue, Securities Act of 1933, Hematological Cancer Research Investment and Education Act, Risk, Annual report, Therapy, Degenerative disease, Drug Quality and Security Act, Investigational New Drug, Board of directors, MHC, FDA, Patient, TCR, Conversation, Board, Immune system, Immunotherapy, Financial condition report, Food and Drug Administration, Company, Selective, Disease, Analysis, COVID-19, Forward-looking statement, Safety, Autoimmune disease, Securities Exchange Act of 1934, Nasdaq, WT1, Histocompatibility, Form 10-Q, GLOBE, Vaccine

Adoptive cell therapysuch as chimeric antigen receptorT-cell(CAR-T) therapies have demonstrated highly encouraging results for some patients but remain limited by the need of cellular ex-vivo manipulation and manufacturing challenges.

Key Points: 
  • Adoptive cell therapysuch as chimeric antigen receptorT-cell(CAR-T) therapies have demonstrated highly encouraging results for some patients but remain limited by the need of cellular ex-vivo manipulation and manufacturing challenges.
  • Similarly, systemic approaches with immunostimulatory molecules, such as interleukin 2 (IL-2) or bispecific molecules, activate T cells indiscriminately and are associated with common severe adverse events, significantly limiting clinical benefit and applicability.
  • Through this design, Immuno-STATs enable disease specificity, targeted selective activation of CD8+ T cells and a larger therapeutic window for IL-2 effectiveness.
  • The modular Immuno-STAT framework is compatible with diverse co-modulators, including immuno-suppressive molecules, with potential to address a variety of autoimmune diseases.

Enzo Biochem to Report Fourth Quarter and Full Year 2021 Financial Results and Business Update on Tuesday, October 12th

Retrieved on: 
Tuesday, September 28, 2021
Securities Act of 1933, Biochemistry, Patent, Company, Securities Exchange Act of 1934, Intellectual property, Risk, Fine chemical, Security (finance)

NEW YORK, NY, Sept. 28, 2021 (GLOBE NEWSWIRE) -- Enzo Biochem, Inc. (NYSE:ENZ), a leading biosciences and diagnostics company, announced today that it will report fourth quarter and fiscal year 2021 financial results on Tuesday, October 12, 2021, before the market open. The announcement will be followed by a live audio webcast and conference call at 8:30am Eastern Time.

Key Points: 
  • A global company, Enzo Biochem utilizes cross-functional teams to develop and deploy products, systems and services that meet the ever-changing and rapidly growing needs of health care today and into the future.
  • Underpinning Enzo Biochems products and technologies is a broad and deep intellectual property portfolio, with patent coverage across a number of key enabling technologies.
  • See Risk Factors in the Companys Form 10-K for the fiscal year ended July 31, 2020.
  • The Company disclaims any obligations to update any forward-looking statement as a result of developments occurring after the date of this release.

BioVaxys Begins Toxicity Study Ahead of CoviDTH IND Submission

Retrieved on: 
Tuesday, September 28, 2021
WuXi Biologics, Patent, Clinical trial, OTCQB, Vaccine, DTH, NASDAQ, FDA, CSE, COVID-19, Patient, Beauty, Toxicity, US Foods, FRA, Company, IND, Severe acute respiratory syndrome coronavirus 2, Drug development, CRO, Safety, Pharmaceutical industry

Although the animal tox study is discretionary, it will not interfere with the IND timing and BioVaxys believes it may provide useful data when the study is completed next month.

Key Points: 
  • Although the animal tox study is discretionary, it will not interfere with the IND timing and BioVaxys believes it may provide useful data when the study is completed next month.
  • CoviDTH is the world's first and only low cost, disposable, point-of-care diagnostic tool that screens for a T-cell response to SARS-CoV-2 in vaccinated patients, or those exposed to SARS-CoV-2.
  • For greater certainty, BioVaxys is not making any express or implied claims that it has the ability to treat the SAR-CoV-2 virus at this time.
  • BioVaxys common shares are listed on the CSE under the stock symbol "BIOV" and trade on the Frankfurt Bourse (FRA: 5LB) and in the US (OTCQB: BVAXF).

Global Healthcare Patent Filing Outsourcing Market Size, Share & Trends Analysis Report 2021 - ResearchAndMarkets.com

Retrieved on: 
Tuesday, September 28, 2021
Medical Devices, Health, United States Patent and Trademark Office, Patent, European Patent Convention, Novartis, CAGR, USPTO, EPO, Organization, Resident, Coronavirus, COVID-19, Boston Scientific, Lifting, European Patent Office, University, Medtronic, Industry, Pharmaceutical industry

The "Global Healthcare Patent Filing Outsourcing Markets 2021-2028: Size, Share & Trends Analysis Report by Domain, by Service (Pre-filing, Filing & Prosecution, Post Grant), by Origin (Resident, Non-resident)" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Global Healthcare Patent Filing Outsourcing Markets 2021-2028: Size, Share & Trends Analysis Report by Domain, by Service (Pre-filing, Filing & Prosecution, Post Grant), by Origin (Resident, Non-resident)" report has been added to ResearchAndMarkets.com's offering.
  • In-house departments of pharmaceutical and medical devices firms typically do not have sufficient time to carry out patent filing processes.
  • Therefore, the market is significantly driven by the growing need for cost-saving and time-saving in patent filing processes.
  • However, with the lifting of COVID-19 related shelter-in-place mandates and commercialization of the vaccine, the bottle necking of patent filing is clearing.

Greenest UV Light Pasteurization Comes to U.S. Dairy Industry

Retrieved on: 
Tuesday, September 28, 2021
Retail, Other Energy, Technology, Other Technology, Alternative Energy, Energy, Food, Beverage, Patent, Temperature, Drink, Taste, Compliance, Agriculture, Agriculture and Agri-Food Canada, Water, Beer, Heat, Bacteria, Virus, Pasteurization, Spore, Drinking water, CEO, Motivation, Milk, UV, UVT, Technology, Research, Water resources, Safety, Doctor of Philosophy, Wine, CO2, Industry, Food preservation

U.S. dairy processors can soon pasteurize milk and other non-transparent liquids with patented ultraviolet (UV) light technology that uses 90% less energy and more than 60% less water than traditional heat/cool pasteurization processes.

Key Points: 
  • U.S. dairy processors can soon pasteurize milk and other non-transparent liquids with patented ultraviolet (UV) light technology that uses 90% less energy and more than 60% less water than traditional heat/cool pasteurization processes.
  • Until recently, however, UV light has been incapable of treating less transparent liquids such as milk to a satisfactory level.
  • Lyras has devoted the last six years to extending the capabilities of UV light with a patent-protected light filter.
  • Founded in Denmark in 2017, Lyras is based on the premise that sustainable pasteurization is possible thanks to ultraviolet light and cold pasteurization.

Capital Digestive Care Finalizes Partnership with Gastrointestinal & Liver Specialists of Tidewater

Retrieved on: 
Tuesday, September 28, 2021
Patent, Insurance, Bop TV, Partnership, GLST, Patient, MSO, Gastrointestinal tract, PLLC, PE, Physician, Health, Gastroenterology, CDC, CEO, Medicine, Growth, Leadership, GI, Solution, Liver, Cancer, 3D ultrasound, Capital, Heartburn, Spring, Institute of Liver and Biliary Sciences, Investment, Bancroft PLLC, GLOBE, Asset management, Health insurance, Hospital

Silver Spring, Maryland, Sept. 28, 2021 (GLOBE NEWSWIRE) -- Capital Digestive Care (CDC) announced that it had finalized its partnership with Gastrointestinal & Liver Specialists of Tidewater, PLLC (GLST), continuing its growth as the largest private gastroenterology (GI) practice in the Mid-Atlantic Region.

Key Points: 
  • Silver Spring, Maryland, Sept. 28, 2021 (GLOBE NEWSWIRE) -- Capital Digestive Care (CDC) announced that it had finalized its partnership with Gastrointestinal & Liver Specialists of Tidewater, PLLC (GLST), continuing its growth as the largest private gastroenterology (GI) practice in the Mid-Atlantic Region.
  • With 34 board-certified physicians, 12 advanced care providers, and 8 locations, GLST is the Tidewater regions leading liver and gastroenterology care practice.
  • Founded in 2009, Capital Digestive Care is the largest private gastroenterology practice in the Mid-Atlantic.
  • About Gastrointestinal & Liver Specialists of Tidewater, PLLC
    For more than 25 years, Gastrointestinal & Liver Specialists of Tidewater, PLLC (GLST) has been the premier practice for liver and gastroenterology in Southeastern Virginia.

RWS Named a Leader in the IDC MarketScape: Content Management Systems for Authenticated Digital Workspaces

Retrieved on: 
Tuesday, September 28, 2021
Marketing, Data Management, Communications, Technology, Software, Networks, Other Communications, Technology, Patent, Language, Human, Management, AIM, Alexa, ICT, London Stock Exchange, Environment, Trimethadione, Communication, Telecommunication, IDC, RWS, Asia, Knowledge management, Contender, Organization, Intellectual property, London, Government, Risk management, RWS, IDC MarketScape, RWS, IDC MARKETSCAPE

RWS, the worlds leading provider of technology-enabled language, content management and intellectual property services, announces that it has been named a Leader in the IDC MarketScape: Content Management Systems for Authenticated Digital Workspaces 2021 Vendor Assessment.

Key Points: 
  • RWS, the worlds leading provider of technology-enabled language, content management and intellectual property services, announces that it has been named a Leader in the IDC MarketScape: Content Management Systems for Authenticated Digital Workspaces 2021 Vendor Assessment.
  • The analyst firms latest report evaluates content management platforms and their ability to support next-generation digital workplace environments.
  • Tridion, connects people, processes, and information through the most complete portfolio of collaborative content management, knowledge management and headless delivery technologies.
  • Click here to download the IDC MarketScape: Content Management Systems for Authenticated Digital Workspaces 2021 Vendor Assessment (doc #US47412921, September 2021).